Q219 US Joint Fluid Market Recap: Marginal Revenue Growth

Written by Freddy Buntoum | 8/12/19 12:55 PM

Q219 saw marginal revenue growth amid single-injection momentum and competitive pricing pressure

The numbers are in and now that we are in the second quarter of 2019, the US Joint Fluid market seems to be getting off its slow-ish start of the year, gaining some momentum with the single-injection segment pushing the aggregate total revenue into positive growth, according to the recently published SmartTRAK Financial Dashboard. This, despite relentless and fierce pricing competition in the multi-injection arena.

Among the many topics covered in the Q219 US Joint Fluid Market Recap* are:

Market Highlights and Overview
Single-Injection Arena: Off and Running - For Good?
3-Injection Arena: Overcrowding Continues
5-Injection Arena – Downward Spiral Continues…

The single-injection segment took over the market lead in Q219, with a commendable 46.9% share of the US Joint Fluid market, reflecting the general trend that the market is further migrating to the lowest treatment cycle according to some suppliers and product users. Meanwhile, 3-injection products dropped down to second place with...

Read the entire Q219 US Joint Fluid Market Recap including news, data, company revenues and analysis*...

*The entire article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.

Request SmartTRAK Subscription Info

View full post